Transplantation Proceedings
Volume 35, Issue 8 , Pages 2837-2842 , December 2003

Cell therapy of renal failure

  • W.H Fissell

      Affiliations

    • Department of Internal Medicine, VA Medical Center, Ann Arbor, Michigan, USA (W.H.F.)
    • ,
  • H.D Humes

      Affiliations

    • Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA (H.D.H.)
    • Corresponding Author InformationAddress reprint requests to David Humes, MD, Professor, Department of Internal Medicine, University of Michigan School of Medicine, 7220 MSRB Ill 0644, 1150 W. Medical Center Dr, Ann Arbor, MI 48109-0726, USA

References 

  1. de Mendonca A, Vincent JL, Suter PM, et al.  Acute renal failure in the ICU (risk factors and outcome evaluated by the SOFA score). Intens Care Med. 2000;26:915
  2. Rihal CS, Textor SC, Gril IDE, et al.  Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259
  3. Guerin C, Girard R, Selli JM, et al.  Initial versus delayed acute renal failure in the intensive care unit. A multicenter prospective epidemiological study. Rhone-Alpes Area Study Group on Acute Renal Failure. Am J Respir Crit Care Med. 2000;161:872
  4. Sarnak MJ, Jaber BL. Mortality-caused by sepsis in patients with end-stage renal disease compared to the general population. Kidney Int. 2000;58:1758
  5. Girndt M, Kohler H, Schiedhelm-Weick E. Production of interleukin-6, tumor-necrosis-factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int. 1995;47:559
  6. Girndt M, Sester U, Sester M, et al.  Impaired cellular-immune function in patients with end-stage renal failure. Nephrol Dial Transplant. 1999;14:2807
  7. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al.  Hypovitaminosis D in medical inpatients. N Engl J Med. 1998;338:777
  8. Humes HD, MacKay SM, Funke AJ, et al.  Tissue engineering of a bioartificial renal tubule assist device (in vitro transport and metabolic). Kidney Int. 1999;55:2502
  9. Humes HD, Buffington DA, MacKay SM, et al.  Replacement of renal function in uremic animals with a tissue-engineered. Nature Biotechnol. 1999;17:451
  10. Humes HD. Bioartificial kidney for full renal replacement therapy. Semi Nephrol. 2000;20:71
  11. Natanson C, Elchenholz PW, Danner RL, et al.  Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med. 1989;169:823
  12. Fissell WH, Dyke DB, Buffington DA, et al.  Bioartificial kidney alters cytokine response and hemodynamics in endotoxin-challenged dogs. Blood Purif. 2002;20:55
  13. Fissell WH, Gutierrez JM, Lou L, et al.  Bioartifical-kidney (BK) protects against gram-negative bacteria-induced septic shock in uremic animals. J Am Soc Nephrol. 2001;12:264A
  14. Fissell WH, Dyke DB, Buffington DA, et al: Bioartificial kidney alters cytokine response and hemodynamics in endotoxin-challenged dogs. J Am Soc Nephrol (in press)
  15. Weitzel WF, Fissell WH, Humes HD. Initial clinical experience with a human proximal tubule cell renal assist device (RAD). J Am Soc Nephrol. 2001;12:279A
  16. Kaihara S, Borenstein J, Koka R, et al.  Silicon micromachining to tissue engineer branched vascular channels for liver fabrication. Tissue Eng. 2000;6:105
  17. Chen CS, Mrksich M, Huang S, et al.  Micropatterned surfaces for control of cell shape, position, and function. Biotechnol Progr. 1998;14:356

PII: S0041-1345(03)01091-1

doi: 10.1016/j.transproceed.2003.10.008

Transplantation Proceedings
Volume 35, Issue 8 , Pages 2837-2842 , December 2003

Article Tools

* Image Usage & Resolution